Vivoryon Therapeutics N.V. to Report Full 12 months 2025 Monetary Outcomes and Enterprise Updates on April 23, 2026
To affix the convention name by way of telephone, members could pre-register and can obtain devoted dial-in particulars to simply and shortly entry the decision by way of the next web site: https://register-conf.media-server.com/register/BIf6c6c97fd8e04610aca204505327e259
It’s steered members dial into the convention name quarter-hour previous to the scheduled begin time to keep away from any delays in attendance.
###
About Vivoryon Therapeutics N.V.Vivoryon is a medical stage biotechnology firm targeted on growing progressive small molecule-based medicines for the remedy of inflammatory and fibrotic problems of the kidney. Pushed by its ardour for ground-breaking science and innovation, the Firm strives to enhance affected person outcomes by altering the course of extreme ailments by way of modulating the exercise and stability of pathologically related proteins. Vivoryon’s most superior program, varoglutamstat, a proprietary, first-in-class orally obtainable QPCT/L inhibitor, is being evaluated to deal with diabetic kidney illness. www.vivoryon.com
More Read
Vivoryon Ahead Trying StatementsThis press launch consists of forward-looking statements, together with, with out limitation, these relating to the enterprise technique, administration plans and aims for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the marketplace for the Firm’s merchandise and forecasts and statements as to when the Firm’s merchandise could also be obtainable. Phrases corresponding to “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and related expressions as they relate to the Firm are meant to determine such forward-looking statements. These forward-looking statements aren’t ensures of future efficiency; relatively they’re primarily based on the Administration’s present expectations and assumptions about future occasions and traits, the financial system and different future situations. The forward-looking statements contain quite a lot of recognized and unknown dangers and uncertainties. These dangers and uncertainties and different elements may materially adversely have an effect on the end result and monetary results of the plans and occasions described herein. The Firm’s outcomes of operations, money wants, monetary situation, liquidity, prospects, future transactions, methods or occasions could differ materially from these expressed or implied in such forward-looking statements and from expectations. In consequence, no undue reliance must be positioned on such forward-looking statements. This press launch doesn’t comprise threat elements. Sure threat elements which will have an effect on the Firm’s future monetary outcomes are mentioned within the printed annual monetary statements of the Firm. This press launch, together with any forward-looking statements, speaks solely as of the date of this press launch. The Firm doesn’t assume any obligation to replace any data or forward-looking statements contained herein, save for any data required to be disclosed by legislation.
For extra data, please contact:
